Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

607534

registered interest
date	21/10/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Docklands Medical Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether Docklands Medical Services Ltd were registered with the Care Quality Commission for the provision of patient transport services during July, August and September 2016; and if he will make a statement.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	49779
answer	answer is ministerial correction date of answer 26/10/2016 answer text <p>The Care Quality Commission (CQC) is the independent regulator of health and adult social care in England. The CQC makes decisions on whether to register providers based on the requirements of the Health and Social Care Act 2008.</p><p> </p><p>The CQC provides assurance that all registered providers are meeting the relevant standards and then through a system of monitoring and ongoing inspection to make sure that standards are being maintained.</p><p> </p><p>The CQC has advised us that for the period July, August and September 2016 Coperforma held the contract with High Weald Lewes Haven Clinical Commissioning Group (CCG) to provide Patient Transport Services to the population of Brighton and elsewhere. The CQC has confirmed that Coperforma were registered to provide patient transport services during the period in question.</p><p> </p><p>The CQC has confirmed that Docklands Medical Services Ltd was not registered to provide patient transport services during the period in question. When it is brought to the attention of the CQC that a provider may have been delivering a regulated activity without registration, they investigate. If the CQC finds evidence to show that regulated activity is or has been delivered whilst unregistered then the CQC may prosecute. It is an offence under the Health and Social Care Act 2008 to carry out a regulated activity - in this case patient transport services - without being registered with the CQC. The CQC is investigating whether an offence has been committed.</p><p> </p><p>The Department understands that <ins class="ministerial">when</ins> the High Weald Lewes Havens CCG identified that the <ins class="ministerial">CQC registration in question related </ins><del class="ministerial">registered provider Coperforma had subcontracted service delivery</del> to Docklands Medical Services <ins class="ministerial">(London)</ins> <del class="ministerial">Ltd</del> <ins class="ministerial">rather than Docklands Medical Services Ltd, they contacted </ins><del class="ministerial">and immediately instructed</del> Coperforma <ins class="ministerial">asking them to confirm the relevant CQC registration status.</ins><del class="ministerial"> to cease using Docklands Medical Services Limited as a subcontractor. This was immediately actioned by Coperforma. </del></p><p><ins class="ministerial">I have also asked NHS England to investigate this provision of transport services during July, August and September 2016.</ins></p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 26/10/2016 18:02:42 question first ministerially corrected 01/11/2016 12:45:02 answering member 1542 label Biography information for Philip Dunne previous answer version 16824 answering member constituency Ludlow answering member printed Mr Philip Dunne answering member 1542 label Biography information for Philip Dunne
tabling member	3930 label Biography information for Caroline Lucas

599539

registered interest
date	11/10/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Circle
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of decisions taken by Circle Holdings PLC in the delivery of musculoskeletal services in Greenwich on the financial capacity of the local healthcare trust to sustain accident and emergency services at University Hospital Lewisham and Queen Elizabeth Hospital Woolwich; and if he will make a statement.
tabling member constituency	Eltham
tabling member printed	Clive Efford
uin	48002
answer	answer is ministerial correction date of answer 17/10/2016 answer text <p>The procurement of local health services by means of competitive tendering is a matter for the local National Health Service.</p><p> </p><p>We are advised by NHS England that Greenwich Clinical Commissioning Group’s Turnaround Director and Musculoskeletal (MSK) Programme Manager met the senior management team of Lewisham and Greenwich Healthcare Trust in March 2016. We understand that the implications of the MSK service procurement were discussed in detail, and that there were no concerns with regard to the viability of any other services the Trust provides.</p><p> </p><p>We are further advised by NHS England that it undertook an assurance of the procurement process for the MSK service in Greenwich in August 2016<ins class="ministerial">. We also understand that NHS Improvement was aware of the procurement and briefly discussed it with the Trust during a standing monthly meeting on 21 June 2016. </ins> <del class="ministerial">and as part of this also met with the Trust to discuss the implications of the procurement for the trust.</del></p><p>We understand that Circle Health has been engaging with Lewisham and Greenwich Healthcare Trust as part of the mobilisation process, including developing clinical and operational delivery plans to provide integrated services.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 17/10/2016 16:19:10 question first ministerially corrected 17/11/2016 14:14:49 answering member 1542 label Biography information for Philip Dunne previous answer version 14633 answering member constituency Ludlow answering member printed Mr Philip Dunne answering member 1542 label Biography information for Philip Dunne
tabling member	165 label Biography information for Clive Efford

579500

registered interest
date	09/09/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Junior Doctors: Pay
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make a comparative assessment of the level of proposed weekend pay under the new junior doctors' contract with weekend pay for (a) prison officers, (b) fire fighters, (c) police officers, (d) call centre workers, (e) consultants and (f) nurses, midwives and physios.
tabling member constituency	Torbay
tabling member printed	Kevin Foster
uin	45817
answer	answer is ministerial correction date of answer 19/09/2016 answer text <p>Junior doctors already work weekends, and they will continue to be fairly rewarded for work undertaken at the weekend using the weekend allowance proposed by the British Medical Association negotiators. Comparative rates are set out in the <ins class="ministerial">attached</ins> table<del class="ministerial"> below</del>.</p><p> </p><p>Because of the allowance based approach to weekend working, the effective hourly rate juniors are paid will vary depending on how many hours they work over how many weekends. In almost all cases junior doctors will receive weekend pay better than other National Health Service professional staff.</p><p> </p><p>A typical rota for a junior doctor involves an average of 6.5 hours a week being worked at weekends. (i.e. they work two long shifts of 13 hours every four weekends). This is split evenly over Saturdays and Sundays and includes night work.</p><p> </p><p>For working those weekend hours the percentage hourly supplement across all the hours worked for different groups of NHS staff would be</p><p>- 66% for a junior doctor (37% for night work plus an additional 7.5% weekend allowance set as a percentage of basic pay)</p><p>- 56% for a band 3 Health Care Assistant (37% for Saturday, 74% for Sunday)</p><p>- 45% for a nurse (30% for Saturday, 60% for Sunday)</p><p>- 33% for a consultant</p><p> </p><p><strong><br /> </strong></p><p> </p><p> </p><table><tbody><tr><td><p><del class="ministerial"> </del></p></td><td><p><del class="ministerial">Payment</del></p></td></tr><tr><td><p><del class="ministerial">Junior doctors</del></p></td><td><p><del class="ministerial">Weekend night shifts ending by 10am. Time plus 37%. Weekend allowance - + 10% 1in2 - + 7.5% - + 6% - + 4% - + 3% - No allowance</del></p></td></tr><tr><td><p><del class="ministerial">Consultants</del></p></td><td><p><del class="ministerial">4hour Programmed Activity is reduced to 3 hours, effectively Time + 33%</del></p></td></tr><tr><td><p><del class="ministerial">Nurses</del></p></td><td><p><del class="ministerial">Time + 30% Saturday time +60% Sunday</del></p></td></tr><tr><td><p><del class="ministerial">Prison officers *</del></p></td><td><p><del class="ministerial">Time + 17%</del></p></td></tr><tr><td><p><del class="ministerial"> </del></p></td><td><p><del class="ministerial"> </del></p></td></tr><tr><td><p><del class="ministerial">Firefighters *</del></p></td><td><p><del class="ministerial">Shift duty covers shifts 24 hours, 7 days. No premia</del></p></td></tr><tr><td><p><del class="ministerial">Police Officers *</del></p></td><td><p><del class="ministerial">Time plus 10% for nights only (8pm-6am)</del></p></td></tr><tr><td><p><del class="ministerial">Call centre workers *</del></p></td><td><p><del class="ministerial">Between Time + 5% and Time + 40%</del></p></td></tr></tbody></table><p> </p><p><del class="ministerial">*Income Data Services study</del></p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 19/09/2016 17:00:01 question first ministerially corrected 20/09/2016 09:51:13 answering member 1542 label Biography information for Philip Dunne attachment 1 file name Comparative weekend pay rates PQ45817.docx title Comparative Pay Rates PQ45817 previous answer version 12257 answering member constituency Ludlow answering member printed Mr Philip Dunne answering member 1542 label Biography information for Philip Dunne
tabling member	4451 label Biography information for Kevin Foster

168664

registered interest
date	08/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many abortions were refused on the grounds on coercion in the last year for which records are available.
tabling member constituency	Fylde
tabling member printed	Mark Menzies
uin	217766
answer	answer is ministerial correction date of answer 15/12/2014 answer text <p>The Department does <ins class="ministerial">not </ins>hold this information.</p><p> </p><p> </p><p> </p><p>We take the issue of coercion seriously and staff working in abortion clinics are experienced and highly skilled in discussing sensitive issues with women and identifying whether there is any coercion or other risks to the woman.</p><p> </p><p> </p><p> </p><p>Women who present for an abortion will always have the opportunity to speak to a health professional on their own at some point during the consultation. Pathways should be in place to refer women to specialised services if coercion is identified.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 15/12/2014 16:55:05 question first ministerially corrected 15/12/2014 17:10:17 answering member 3918 label Biography information for Jane Ellison previous answer version 33589 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
tabling member	3998 label Biography information for Mark Menzies

167082

registered interest
date	01/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sickle Cell Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the annual cost to the NHS of treating sickle cell anaemia.
tabling member constituency	Wolverhampton South East
tabling member printed	Mr Pat McFadden
uin	216529
answer	answer is ministerial correction date of answer 08/12/2014 answer text <p>There are an estimated 250,000 people with <ins class="ministerial">the</ins> sickle cell <ins class="ministerial">trait</ins> <del class="ministerial">anaemia</del> in the United Kingdom. The Department has made no estimation of the annual cost of treating sickle cell anaemia in the National Health Service nor does it hold information on the total NHS spend on sickle cell anaemia.</p><p> </p><p> </p><p> </p><p>The Department does hold estimated costs for admitted patient care episodes as reported by Healthcare Resource Groups. In 2013-14 the total estimated figure for sickle anaemia was £23.8 million; in 2012-13 it was £21.9 million. This figure does not include other costs such as primary and social care.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/12/2014 15:12:22 question first ministerially corrected 10/12/2014 16:29:44 answering member 3918 label Biography information for Jane Ellison previous answer version 32239 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
tabling member	1587 label Biography information for Pat McFadden

100887

registered interest
date	24/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Asthma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211918
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100723

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211734
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100728

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211730
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall

100730

registered interest
date	23/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Osteoporosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	211735
answer	answer is ministerial correction date of answer 29/10/2014 answer text <p>The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p> </p><table><tbody><tr><td> </td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td colspan="6"><p>Asthma</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></p></td><td><p><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></p></td><td><p><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></p></td><td><p><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></p></td><td><p><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.3</p></td><td><p>1.5</p></td><td><p>0.8</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>2.6</p></td><td><p>3.4</p></td><td><p>2.4</p></td><td><p>3.4</p></td><td><p>3.8</p></td></tr><tr><td><p>Total</p></td><td><p><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></p></td><td><p><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></p></td><td><p><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></p></td><td><p><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></p></td><td><p><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></p></td></tr><tr><td colspan="6"><p>Motor Neurone Research</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>7.0</p></td><td><p>7.5</p></td><td><p>4.2</p></td><td><p>4.1</p></td><td><p>3.6</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>0.7</p></td><td><p>0.5</p></td></tr><tr><td><p>Total</p></td><td><p>7.3</p></td><td><p>7.8</p></td><td><p>5.0</p></td><td><p>5.5</p></td><td><p>5.1</p></td></tr><tr><td colspan="6"><p>Osteoporosis</p></td></tr><tr><td><p>Medical Research Council</p></td><td><p>6.2</p></td><td><p>5.4</p></td><td><p>5.1</p></td><td><p>4.6</p></td><td><p>5.9</p></td></tr><tr><td><p>Other Research Councils and Innovate UK</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.4</p></td><td><p>1.0</p></td></tr><tr><td><p>National Institute for Health Research</p></td><td><p>0.3</p></td><td><p>0.7</p></td><td><p>0.8</p></td><td><p>1.3</p></td><td><p>1.8</p></td></tr><tr><td><p>Total</p></td><td><p>6.5</p></td><td><p>6.1</p></td><td><p>6.0</p></td><td><p>6.3</p></td><td><p>8.7</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.</p><p> </p><p> </p><p> </p><p>Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.</p><p> </p><p> </p><p> </p><p>Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/10/2014 17:12:28 question first ministerially corrected 13/11/2014 10:22:56 answering member 4020 label Biography information for George Freeman previous answer version 25123 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4026 label Biography information for Liz Kendall